| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Exercise Physiology and Biomechanics Laboratory (Drs. Verbessem, Eijnde, Van Leemputte, and Hespel) and Motor Control Laboratory (Dr. Swinnen), Department of Kinesiology, and Adapted Physical Activity and Cardiorespiratory Rehabilitation Unit (Dr. Vanhees), Department of Rehabilitation Sciences, Faculty of Physical Education and Physiotherapy; and Neurology Unit (J. Lemiere and Dr. Dom), Department of Neurosciences and Psychiatry, and Hypertension and Cardiovascular Rehabilitation Unit (Dr. Vanhees), Department of Molecular and Cardiovascular Research, Faculty of Medicine, K.U. Leuven, Belgium.
Address correspondence and reprint requests to Dr. Peter Hespel, Exercise Physiology and Biomechanics Laboratory, Faculty of Physical Education and Physiotherapy, Tervuursevest 101, B-3001 Leuven, Belgium; e-mail: Peter.Hespel{at}flok.kuleuven.ac.be
Objective: To evaluate the effect of creatine (Cr) supplementation (5 g/day) in Huntington’s disease (HD).
Methods: A 1-year double-blind placebo-controlled study was performed in 41 patients with HD (stage I through III). At baseline and after 6 and 12 months, the functional, neuromuscular, and cognitive status of the patients was assessed by a test battery that consisted of 1) the Unified Huntington’s Disease Rating Scale (UHDRS), 2) an exercise test on an isokinetic dynamometer to assess strength of the elbow flexor muscles, 3) a maximal exercise test on a bicycle ergometer to evaluate cardiorespiratory fitness, and 4) a test to assess bimanual coordination ability. Following the baseline measurements, the subjects were assigned to either a creatine (n = 26) or a placebo group (n = 15).
Results: Scores on the functional checklist of the UHDRS (p < 0.05), maximal static torque (p < 0.05), and peak oxygen uptake (p < 0.05) decreased from the start to the end of the study, independent of the treatment received. Cognitive functioning, bimanual coordination ability, and general motor function (total motor scale, UHDRS) did not change from baseline to 1 year in either group.
Conclusion: One year of Cr intake, at a rate that can improve muscle functional capacity in healthy subjects and patients with neuromuscular disease (5 g/day), did not improve functional, neuromuscular, and cognitive status in patients with stage I to III HD.
Presented in part at the 54th annual meeting of the American Academy of Neurology; Denver, CO; April 2002.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 14 issue to find the title link for this article.
Received . Accepted in final form .
This article has been cited by other articles:
|
|
 |
|
  J. Shao and M. I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R115 - R123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG Neurology, January 24, 2006; 66(2): 250 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Derave, B. O. Eijnde, M. Ramaekers, and P. Hespel No effects of lifelong creatine supplementation on sarcopenia in senescence-accelerated mice (SAMP8) Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E272 - E277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Tabrizi, A. M. Blamire, D. N. Manners, B. Rajagopalan, P. Styles, A.H.V. Schapira, and T. T. Warner High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study Neurology, May 10, 2005; 64(9): 1655 - 1656. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
